A Phase 3 Study of Tenapanor to Treat Hyperphosphatemia in ESRD Patients on Dialysis
Status:
Completed
Trial end date:
2020-02-27
Target enrollment:
Participant gender:
Summary
This Phase 3, 26-week, open label study with a 12-week, placebo-controlled, randomized
withdrawal period followed by an open label long term safety extension will evaluate the
safety and efficacy of tenapanor to treat hyperphosphatemia in end-stage renal disease (ESRD)
on hemodialysis and peritoneal dialysis.